HOME PRODUCTS COMPANY CONTACT FAQ

Research Dictionary Pharma

Sign Up FREE or Login

GB-0139

thio-digalactoside inhibitor

Also Known As:

GB 0139; GB0139; TD-139

Networked: 5 relevant articles (0 outcomes, 0 trials/studies)

Bio-Agent Context: Research Results

Organic Chemicals: 133
- Sulfur Compounds: 278
  - Thioglycosides: 17
    - Thiogalactosides: 1
      - GB-0139: 5
Carbohydrates: 22023
- Glycosides: 2119
  - Galactosides: 43
    - Thiogalactosides: 1
      - GB-0139: 5
  - Thioglycosides: 17
    - Thiogalactosides: 1
      - GB-0139: 5
Heterocyclic Compounds: 198
- 1-Ring Heterocyclic Compounds
  - Azoles: 2138
    - Triazoles: 1533
      - GB-0139: 5

Experts

1.	Dobie, Ross: 1 article (01/2021)
2.	Henderson, Neil C: 1 article (01/2021)
3.	Humphries, Duncan C: 1 article (01/2021)
4.	Mackinnon, Alison C: 1 article (01/2021)
5.	Mills, Ross: 1 article (01/2021)
6.	Sethi, Tariq: 1 article (01/2021)
7.	Alvala, Mallika: 1 article (08/2020)
8.	Jayanthi, Sivaraman: 1 article (08/2020)
9.	Munagalasetty, Sharon: 1 article (08/2020)
10.	Sanam, Swetha: 1 article (08/2020)

Related Diseases

1.	Idiopathic Pulmonary Fibrosis 01/01/2022 - "GB0139 is a Gal-3 inhibitor currently under clinical investigation for the treatment of idiopathic pulmonary fibrosis. " 01/01/2021 - "An inhaled Gal-3 inhibitor, GB0139, is undergoing Phase II clinical development for idiopathic pulmonary fibrosis (IPF). " 10/13/2022 - "We recently found a high affinity (nM) thiodigalactoside GB0139 which currently is in clinical development (PhIIb) as an inhaled treatment of idiopathic pulmonary fibrosis. "
2.	COVID-19 08/10/2020 - "In addition, it warrants a swift examination of TD-139 for treating COVID-19." 01/01/2023 - "Conclusions: In COVID-19 pneumonitis, inhaled GB0139 was well-tolerated and achieved clinically relevant plasma concentrations with target engagement. " 01/01/2023 - "Objectives: Primary outcomes were safety and tolerability of inhaled GB0139 as an add-on therapy for patients hospitalized with COVID-19 pneumonitis. " 01/01/2023 - "We hypothesized that GB0139, a potent inhaled thiodigalactoside galectin-3 inhibitor with antiinflammatory and antifibrotic actions, would be safely and effectively delivered in COVID-19 pneumonitis. "
3.	Acute Lung Injury 01/01/2022 - "Galectin-3 inhibitor GB0139 protects against acute lung injury by inhibiting neutrophil recruitment and activation."
4.	Lung Injury 01/01/2022 - "Conclusion: These data indicate that Gal-3 adopts a pro-inflammatory role following the early stages of lung injury and supports the development of GB0139, as a potential treatment approach in ALI."
5.	Pneumonia (Pneumonitis) 01/01/2023 - "Conclusions: In COVID-19 pneumonitis, inhaled GB0139 was well-tolerated and achieved clinically relevant plasma concentrations with target engagement. " 01/01/2023 - "Objectives: Primary outcomes were safety and tolerability of inhaled GB0139 as an add-on therapy for patients hospitalized with COVID-19 pneumonitis. " 01/01/2023 - "We hypothesized that GB0139, a potent inhaled thiodigalactoside galectin-3 inhibitor with antiinflammatory and antifibrotic actions, would be safely and effectively delivered in COVID-19 pneumonitis. "

Related Drugs and Biologics

1.	Galectin 3 (LGALS3)
2.	thiodigalactoside

Related Therapies and Procedures

1.	Therapeutics